Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study

Key Points • In myeloproliferative neoplasms, frailty is more prevalent compared with matched controls and distinct from aging and comorbidities.• Higher frailty is associated with worse OS independent of advanced age and comorbidity burden.

[1]  S. Alibhai,et al.  Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study , 2021, British journal of haematology.

[2]  S. Bonassi,et al.  Association of inflammatory mediators with frailty status in older adults: results from a systematic review and meta-analysis , 2020, GeroScience.

[3]  M. Kivipelto,et al.  Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care , 2020, Journal of the American Medical Directors Association.

[4]  A. Gruneir,et al.  Prefrailty in Older Adults: A Concept Analysis. , 2020, International journal of nursing studies.

[5]  C. Earle,et al.  Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada , 2020, Leukemia & lymphoma.

[6]  P. Dickman,et al.  Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden , 2020, Journal of internal medicine.

[7]  B. Leber,et al.  An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring , 2019, Leukemia.

[8]  L. Fried,et al.  Frailty: implications for clinical practice and public health , 2019, The Lancet.

[9]  C. van Walraven,et al.  Derivation and Validation of a Generalizable Preoperative Frailty Index Using Population-based Health Administrative Data. , 2019, Annals of surgery.

[10]  H. Cohen,et al.  Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Dickman,et al.  Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms , 2018, Annals of Internal Medicine.

[12]  Jenny Ploeg,et al.  Interventions to prevent or reduce the level of frailty in community-dwelling older adults: a scoping review of the literature and international policies , 2017, Age and ageing.

[13]  M. Makary,et al.  Inclusion of Sarcopenia Outperforms the Modified Frailty Index in Predicting 1-Year Mortality among 1,326 Patients Undergoing Gastrointestinal Surgery for a Malignant Indication. , 2016, Journal of the American College of Surgeons.

[14]  H. Hasselbalch,et al.  MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives , 2015, Mediators of inflammation.

[15]  P. Selby,et al.  The prevalence and outcomes of frailty in older cancer patients: a systematic review. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Ewout W Steyerberg,et al.  Predictive accuracy of novel risk factors and markers: A simulation study of the sensitivity of different performance measures for the Cox proportional hazards regression model , 2015, Statistical methods in medical research.

[17]  A. Buliková,et al.  Second malignancies in philadelphia-negative myeloproliferative neoplasms-single-center experience. , 2014, Anticancer research.

[18]  M. Bonnefoy,et al.  Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial. , 2013, European Journal of Cancer.

[19]  H. Wildiers,et al.  Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  P. Dickman,et al.  Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Stuck,et al.  Examining five- and ten-year survival in older women with breast cancer using cancer-specific geriatric assessment. , 2012, European journal of cancer.

[22]  S. Culine,et al.  Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  O. Dalesio,et al.  Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Kenneth Rockwood,et al.  Changes in relative fitness and frailty across the adult lifespan: evidence from the Canadian National Population Health Survey , 2011, Canadian Medical Association Journal.

[25]  A. Tefferi,et al.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Q. Xue.  The frailty syndrome: definition and natural history. , 2011, Clinics in geriatric medicine.

[27]  M. Sylvia,et al.  Using the ACG® casemix system in population health management programs at Johns Hopkins , 2009, BMC Health Services Research.

[28]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[29]  R. Varadhan,et al.  Initial manifestations of frailty criteria and the development of frailty phenotype in the Women's Health and Aging Study II. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[30]  Thomas M Gill,et al.  Transitions between frailty states among community-living older persons. , 2006, Archives of internal medicine.

[31]  L. Ferrucci,et al.  Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. , 2004, The journals of gerontology. Series A, Biological sciences and medical sciences.

[32]  P W Lavori,et al.  Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. , 2000, Controlled clinical trials.

[33]  P. De,et al.  Health Services Data: The Ontario Cancer Registry (a Unique, Linked, and Automated Population-Based Registry) , 2016 .

[34]  P. de Souto Barreto.  One operational definition by population: the need for local evaluations of frailty. , 2011, Journal of physiological anthropology.